Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

The move to deny coverage for an approved orphan drug is ‘highly unusual,' NORD VP says. 'We certainly hope this isn’t going to set a precedent.'

National health insurer Anthem Inc. has determined it won’t cover Sarepta Therapeutics Inc.’s drug for Duchenne muscular dystrophy Exondys 51 (eteplirsen) because the drug lacks data showing it is clinically effective.

“The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet